Benzodiazepine compound and pharmaceutical composition

IPC classes for russian patent Benzodiazepine compound and pharmaceutical composition (RU 2496775):

C07D513/04 - Ortho-condensed systems

C07D495/04 - Ortho-condensed systems

C07D491/04 - Ortho-condensed systems

C07D417/14 - containing three or more hetero rings

C07D409/14 - containing three or more hetero rings

C07D405/14 - containing three or more hetero rings

C07D401/14 - containing three or more hetero rings

C07D401/12 - linked by a chain containing hetero atoms as chain links

C07D243/12 - 1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines

A61P9/06 - Antiarrhythmics

A61K31/551 -

Another patents in same IPC classes:

Iap inhibitors / 2491276

Invention relates to compounds of formula: U₁-M-U₂, where U₁ and U₂ have general formula (I), where: G stands for: IVb IVd ive, and values M, X₁, X₂, R₂, R₃, R₃', R₄, R₄', R₅, R₅', R₆, R₆', R₇, Z₇, Z₂, Z₃, Z₄, Q₂ are given in item 1 of the formula.

5-substituted indazole as kinase inhibitors / 2487873

Present invention refers to compounds of formula (I) or pharmaceutically acceptable salts thereof wherein A, R₁, R₂, R₃ and m are specified in the patent claim. The present invention also refers to the number of specific compounds, and to a pharmaceutical composition containing the above compounds effective for inhibition of kinases, such as glycogen synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus kinase (JAK), AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.

3-phenylpyrazolo[5,1-b]thiazole derivative / 2482120

Invention refers to compounds of formula (I) and salts thereof wherein R¹ represents -A¹¹-A¹²-; R² represents tetrahydrofurylmethyl, tetrahydropyranylmethyl or tetrahydropyranyl; A¹¹ represents a single bond, methylene or 3,2-ethylene; A¹² represents C_1-6 alkyl, C_3-6 cycloalkyl or C_3-6 cycloalkyl containing methyl; R³ represents methoxy, cyano, cyclobutyloxymethyl, methoxymethyl or ethoxymethyl; and R⁴ represents methoxy or chlorine. Also, the invention also refers to a pharmaceutical composition possessing corticotrophin-releasing factor (CRF) receptor antagonist activity, containing a compound of formula (I), to a therapeutic/preventive agent, and a method of treating the diseases specified in the patent claim.

Condensed heterocyclic compound / 2480473

Invention relates to compounds of formula 1 , where X and T are N or C, Q is a (3-7)-member aromatic ring which contains 0-3 nitrogen atoms as ring members, and which is optionally benzo-condensed and is substituted with oxo; C₁-C₆-alkyl; halogen- C₁-C₆-alkyl; hydroxy-C₁-C₆-alkyl; C₁-C₆-alkoxy; C₆-C₁₀-aryl; or a (3-7)-member heteroaryl containing 1-3 oxygen atoms, P is C₁-C₆-alkyl, optionally substituted with a halogen, and R is a group selected from: (i) -C₁-C₆-alkyl-R¹, (ii) -NR²R³, (iii) -O-R⁴, (iv) -S-R⁵, (v) -C (=O))-R⁶, (vi) optionally substituted (3-7)-member heteroaryl containing 1-4 heteroatoms selected from a nitrogen atom, an oxygen atom and a sulphur atom, (vi) optionally substituted (3-7)-member heteroatom containing 1-4 heteroatoms selected from a nitrogen atom, an oxygen atom and a sulphur atom, (vii) optionally substituted, saturated or partially unsaturated, separate or condensed (3-10)-member heterocyclic ring containing 1-4 heteroatoms selected from a nitrogen atom, an oxygen atom and a sulphur atom, (viii) azido; where each R¹, R², R³, R⁴, R³, R⁶, is as described in the claim. The invention also relates to a pharmaceutical composition for preventing and treating a vascular disease, which contains a compound of formula 1.

2-aza-bicyclo[3,3,0]octane derivatives / 2478099

Invention relates to a 2-aza-bicyclo[3.3.0]octane derivative of formula , with stereogenic centres in a (1S,3S,5S)-configuration, where A is a thiazolyl which is unsubstituted or monosubstituted, where the substitute is independently selected from a group comprising C_1-4alkyl, C_3-6cycloalkyl and NH₂; B is phenyl which is unsubstituted or mono- or disubstituted, where the substitutes are independently selected from a group comprising C_1-4alkyl, trifluoromethyl, NHC(O)CH₃ and halogen; and R¹ is an imidazo[2,1·b]thiazolyl or benzoisoxazolyl group, where said groups are independently unsubstituted or monosubstituted, where the substitutes are independently selected from a group comprising C_1-4alkyl; or R¹ is a 2,3-dihydrobenzofuranyl group; or a pharmaceutically acceptable salt. The 2-aza-bicyclo[3.3.0]octane derivative of formula (I) is as a medicinal agent having the activity of orexin receptor antagonists.

Condensed aminohydrothiazine derivative / 2476431

Invention refers to a compound of general formula:

Bicyclosulphonyl acid (bcsa) and use thereof as therapeutic agent / 2472784

Invention relates to bicyclosulphonyl acid (BCSA) compounds of formula: where: where each of -R^pw, -R^px, -R^PY, and -R^PZ independently denotes H or -R^RS1; each -R^RS1 independently denotes -F, -Cl, -Br, -I, -R^A1, -CF₃, -OH, -OCF₃ or -OR^A1; where each R^A1 independently denotes C_1-4alkyl, phenyl or benzyl; and additionally, two neighbouring -R^RS1 groups can together form -OCH₂O-, -OCH₂CH₂O- or -OCH₂CH₂CH₂O-; -R^AK independently denotes a covalent bond, -(CH₂)- or -(CH₂)₂-; -R^N independently denotes -R^NNN, or -L^N-R^NNN; the rest of the values of the radicals are given in claim 1, which act as inhibitors of inhibitors of tumor necrosis factor-α converting enzyme (TACE).

3-aza-bicyclo[3,3,0]octane compounds / 2471796

Invention relates to 3-aza-bicyclo[3.3.0]octane derivatives of formula , where R¹ and R² are hydrogen, C_1-4alkyl or fluorine; R³ is a phenyl which is unsubstituted, mono- or disubstituted, where the substitutes are independently selected from a group comprising C_1-4alkyl, C_1-4alkoxy group, trifluoromethyl, trifluoromethoxy group and halogen; 2,3-dihydrobenzofuranyl; 2,3-dihydrobenzo[1,4]dioxynyl; or isoxazolyl, pyridyl, indazolyl, benzofuranyl, benzoxazolyl, benzoisoxazolyl, benzothiazolyl, benzoisothiazolyl, pyrrolo[2,1b]thiazolyl, imidazo[ 1,2-a]pyridinyl or imidazo[2,1-b]thiazolyl, where said groups are unsubstituted, mono- or disubstituted, where the substitutes are independently selected from a group comprising C₁-₄alkyl, C_1-4alkoxy group, halogen and trifluoromethyl; A is or ; R⁴ is C_1-4alkyl or -NR⁶R⁷; R⁶ is hydrogen or C_1-4alkyl; R⁷ is hydrogen or C_1-4alkyl; and D is a phenyl which is unsubstituted, mono- or disubstituted, where the substitutes are independently selected from a group comprising C_1-4alkyl, C_1-4alkoxy group, trifluoromethyl and halogen; or a pharmaceutically acceptable salt of such a compound. 3-aza-bicyclo[3.3.0]octane derivatives or a pharmaceutically acceptable salt thereof are used as a medicinal agent having the activity of orexin receptor antagonists.

3-amino-6-(1-aminoethyl)tetrahydropyrane derivatives / 2471795

Invention refers to new antibacterial compounds of formula I

Compositions for activation of lipoprotein lipase containing benzene derivatives / 2466725

Invention refers to an agent for activation of lipoprotein lipase containing a benzene derivative of general formula (1) which is used for preventing and treating hyperlipidemia and obesity. The invention also refers to the benzene derivatives of general formula (1a).

Protein tyrosine kinase activity inhibitors / 2495044

Invention refers to a compound of formula (I): and pharmaceutically acceptable salts, diastereoisomers and enantiomers thereof, wherein D is specified in a group consisting of , and , M is ; Z is -O-; Ar is a 6-member aromatic ring system substituted by 0 to 4 R² groups; and G is or ; the other radical values are presented in cl.1 of the patent claim, as well as to using them for inhibiting protein tyrosine kinase inhibition.

Thienopyridazine compounds, preparing them, pharmaceutical compositions containing them, and using them / 2494103

Invention refers to thienopyridazine compounds of formula (I) and to pharmaceutically acceptable salts and hydrates thereof, wherein R1 and R2 independently mean H or C1-4 alkyl; R3 means a saturated or unsaturated 5- or 6-members ring containing N, S or O, or optical isomers thereof, R4 means phenyl, monosubstituted or disubstituted halogen. The invention also refers to a method for preparing the above compounds and to a pharmaceutical composition for treating and preventing tumour diseases containing the above compounds.

Substituted azepine derivatives, pharmaceutical composition and method of treating diseases, disorders and/or pathological conditions wherein 5ht_2c-receptor function modulation is desirable / 2485125

Present invention refers to organic chemistry, namely azepine derivatives of general formula (I) or pharmaceutically acceptable salts thereof, wherein X represents S; R₁ and R₂ are independently specified in a group of substitutes consisting of H, halogen, C_1-8-alkyl, C_1-8-alkylphenyl, C_2-8-alkenyl, OR₅, CON(R₅)₂, SO₂N(R₅)₂, phenyl, if necessary containing up to three substitutes of C_1-4alkyl, halogen or C_1-4alkoxy-groups; R₃ is specified in a group consisting of H, C_1-8-alkyl, OR₅; R_3a represents H, or R₂ and R₃ together represent a five-merous saturated cycle; R₄ is specified in a group consisting of H, C_1-8-alkyl; R_4a represents H, or R₄ and R_4a together represent the substitute -CH₂CH₂-; R₅ is specified in a group consisting of C_1-8-alkyl, or R₅ together with the atom whereto attached represents pyrrolidinyl; or R₁ represents 4-trifluoromethoxyphenyl or 2-trifluoromethylphenyl, then X represents S, and R₂, R₃, R_3a, R₄ and R_4a represents hydrogen, provided a derivative is other than 8- phenyl-5,6,7,8-tetrahydro-4H-thieno[2,3-d]azepin-3-ol and 2-bromo-8-phenyl-5,6,7,8-tetrahydro-4H-thieno[2,3-d]azepine-3-ol. Also, the invention refers to a pharmaceutical composition of the compounds of formula (I) and a method treating disorders on the basis of the use of the compound of formula (I).

Crystals of prasugrel hydrobromate / 2484094

Invention describes crystals of 2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine (prasugrel) hydrobromate, comprisions of crystals and pharmaceutical compositions containing them for preventing and treating the diseases associated with thrombus or embolism in an animal.

Condensed heterocyclic compound / 2480473

Thieno[3,2-c]pyridine derivatives as kinase inhibitors for use in cancer treatment / 2480472

Compound is N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl-N'-(3-fluorophenyl)urea, N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl-N'-[4-(difluoromethoxy)phenyl]urea, N-[4-(4-amino-7-{l-[(2S)-2-hydroxypropyl)-1H-pyrazol-4-yl}thieno[3,2-c]pyridin-3-yl)phenyl]-N'-(3-methylphenyl)urea, N-(4- {4-amino-7-[1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl-N'-(4-methoxyphenyl)urea, N-[4-(4-amino-7-{1-[(2S)-2,3-dihydroxypropyl)-1H-pyrazol-4-yl}thieno[3,2-c]pyridin-3-yl)phenyl]-N'-(4-methoxyphenyl) or therapeutically acceptable salts thereof. A pharmaceutical composition based on said compounds is also disclosed.

N-acylated 3-amino-4,6-dimethylthieno[2,3-b]pyridine-2-carboxamides as antidotes of 2,4-d on sunflower / 2475490

Invention relates to N-acylated 3-amino-4,6-dimethyl-thieno[2,3-b]pyridine-2-carboxamides, which exhibit antidote activity on 2,4-dichlorophenoxyacetic acid on sunflower.

Piperidine derivative / 2475485

Present invention relates to a piperidine derivative of general formula (I)

Therapeutic agent on pyrroline derivates for prevention of tumorous cell death, method for preparing it and method for using it / 2473551

Invention refers to compound presented by Formula

Intracellular calcium modulating compounds / 2472791

Invention relates to compounds of formula (I): where: A, J, R1, R4, X, Z are given in claim 1, and to a pharmaceutical composition containing such compounds, which modulate activity of store-operated calcium (SOC) channels. The present invention also describes methods of using such SOC channel modulators to treat diseases or conditions where inhibition of activity of SOC channels can be beneficial.

FIELD: medicine, pharmaceutics.

SUBSTANCE: there are described new benzodiazepine compounds of general formula , wherein each R¹, R², R³ and R⁴ independently represent hydrogen or alkyl, or R² and R³ together represent lower alkylene; A¹ is lower alkylene optionally substituted by hydroxy; and R⁵ is a fragment of formula , wherein each R⁶ and R⁷ independently represents hydrogen, lower alkyl, cycloalkyl, phenyl, furyl, thienyl, pyrazolyl, etc.; each X_A and X_B independently represents a bond, lower alkylene, -CO-, -SO₂- etc., a pharmaceutical composition containing them, and using the above compound as the pharmaceutical composition or for preparing the same.

EFFECT: new compounds may be used for preventing and treating cardiac arrhythmia.

8 cl, 1047 ex, 78 tbl

The text descriptions are given in facsimile form.

1. Connection benzodiazepine represented by the General formula (1)

or its pharmaceutically acceptable salt,
where R¹, R², R³and R⁴each independently is hydrogen or lower alkyl;
R²and R³may be associated with the formation of the lower alkylene;
And¹is the lowest alkylene, optionally substituted by one or more hydroxy; and
R⁵is a group represented by

where R⁶and R⁷each independently is hydrogen, lower alkyl, lower cycloalkyl, phenyl, naphthyl, fullam, teinila, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, pirrallo, triazolam, pyridium, pyrimidinium, pyridazinyl, pyrazinium, imidazo[2,1-b]what iatlian, thieno[2,3-b]pyrazinium, 2,3-dihydroimidazo[2,1-b]thiazolium, benzothiazolium, indolium, imidazo[1,2-a] pyridium, benzothieno, benzimidazolyl, 2,3-dihydrobenzo[b]fullam, benzofuran, indusrial, furo[2,3-C]pyridium, furo[3,2-C]pyridium, thieno[2,3-C]pyridium, thieno[3,2-C]pyridium, thieno[2,3-b]pyridium, benzo[1,3]dioxolan, benzisoxazole, pyrazolo[2,3-a]-pyridium, indolizinyl, 2,3-dihydroindole, ethanolism, 1,2,3,4-tetrahydro-1H-ethanolism, barbastella, 3,4-dihydroorotase, chinaillon, romaniam, 5,6,7,8-tetrahydroisoquinoline, 3,4-dihydro-1H-ethanolism, naphthyridine, 1,4-benzodioxane, cinnoline, khinoksalinona or 2,3-dihydrobenzo-1,4-oxazinyl, each of which is optionally substituted by one or more substituents selected from the group consisting of the following (4-1)to(4-32):
(4-1) cyano,
(4-2) hydroxy,
(4-3) halogen,
(4-4) lower alkyl, optionally substituted by one or more substituents selected from the group consisting of halogen, imidazolyl, morpholinyl and lower alkoxy,
(4-5) lower alkoxy, optionally substituted by one or more substituents selected from the group consisting of amino and lower alkylamino,
(4-6) pyridyl,
(4-7) tanila,
(4-8) piperazinil, optionally substituted by one or more lower alkyl,
(4-9) phenyl, optionally substituted by one or bol is e lower alkoxy,
(4-10) pyrazolyl, optionally substituted by one or more lower alkyl,
(4-11) pyrimidinyl, optionally substituted by one or more lower alkyl,
(4-12) piperidyl, optionally substituted by one or more lower alkyl,
(4-13) furil,
(4-14) carboxy,
(4-15) lower alkoxycarbonyl,
(4-16) amino, optionally substituted by one or more substituents selected from the group consisting of lower alkanoyl, lower alkylsulfonyl and lower alkyl,
(4-17) lower alkylthio,
(4-18) triazolyl,
(4-19) imidazolyl,
(4-20) pyrrolidinyl, optionally substituted by one or more oxo,
(4-21) lower alkylsulfonyl,
(4-22) lower alkylenedioxy, optionally substituted by one or more halogen,
(4-23) nitro,
(4-24) oxazolyl
(4-25) thiazolyl, optionally substituted by one or more lower alkyl,
(4-26) sulfo,
(4-27) pyridyloxy,
(4-28) lower alkylenedioxy,
(4-29) lower alkanolamine,
(4-30) oxo,
(4-31) morpholinyl and
(4-32) lower alkanoyl;
X_Aand X_Beach is independently a bond, lower alkylene, lower Alcanena, -CO-, -SO₂-, -SO₂-lower alkylene, -CO-lower alkylene, -CO-lower Alcanena, lower alkylene-N(lower alkyl)-CO-lower alkylene, lower alkylene-N(lower alkyl)-, lower alkylene-M(lower alkyl)-CO - or lower alkylene-O-.

2. Connection benzodiazepine represented by the General formula (1) or its pharmaceutically acceptable salt according to claim 1,
where R⁶and R⁷each is one of (1)to(52):
(1) hydrogen,
(2) lower alkyl,
(3) lower cycloalkyl,
(4) phenyl, optionally substituted by one or more substituents selected from the group consisting of (4-1)to(4-25):
(4-1) cyano,
(4-2) hydroxy,
(4-3) halogen,
(4-4) lower alkyl, optionally substituted by one or more substituents selected from the group consisting of halogen, imidazolyl and morpholinyl,
(4-5) lower alkoxy, optionally substituted by one or more substituents selected from the group consisting of amino and lower alkylamino,
(4-6) pyridyl,
(4-7) tanila,
(4-8) piperazinil, optionally substituted by one or more lower alkyl,
(4-9) phenyl,
(4-10) pyrazolyl, optionally substituted by one or more lower alkyl,
(4-11) pyrimidinyl, optionally substituted by one or more lower alkyl,
(4-12) piperidyl, optionally substituted by one or more lower alkyl,
(4-13) furil,
(4-14) carboxy,
(4-15) lower alkoxycarbonyl,
(4-16) amino, optionally substituted by one or more substituents selected from the group consisting of lower alkanoyl and lower alkylsulfonyl,
(4-17) lower alkylthio,
(4-18) triazolyl,
(4-19) them is Azolla,
(4-20) pyrrolidinyl, optionally substituted by one or more oxo,
(4-21) lower alkylsulfonyl,
(4-22) lower alkylenedioxy, optionally substituted by one or more halogen,
(4-23) nitro,
(4-24) oxazolyl, and
(4-25) thiazolyl, optionally substituted by one or more lower alkyl,
(5) naphthyl,
(6) furil, optionally substituted by one or more substituents selected from the group consisting of lower alkyl, optionally substituted with halogen, carboxy, sulfo, pyridyloxy, lower alkoxycarbonyl and phenyl,
(7) tanila, optionally substituted by one or more substituents selected from the group consisting of lower alkyl, lower alkylenedioxy, carboxy, halogen, pyridyl, lower alkoxy, lower alkoxycarbonyl, oxazolyl and Furie,
(8) imidazolyl, optionally substituted by one or more substituents selected from the group consisting of phenyl, lower alkyl and halogen,
(9) pyrazolyl, optionally substituted by one or more substituents selected from the group consisting of lower alkyl, optionally substituted with halogen, halogen, phenyl, optionally substituted lower alkoxy, purile and tanila,
(10) oxazolyl, optionally substituted by one or more substituents selected from the group consisting of lower alkyl and phenyl,
(11) isoxa olila, optionally substituted by one or more substituents selected from the group consisting of phenyl, lower alkyl, tanila and Furie,
(12) thiazolyl, optionally substituted by one or more substituents selected from the group consisting of lower alkyl, optionally substituted lower alkoxy, phenyl and lower alkanolamine,
(13) pyrrolyl, optionally substituted by one or more substituents selected from the group consisting of lower alkyl and lower alkoxycarbonyl,
(14) triazolyl, optionally substituted by one or more lower alkyl,
(15) pyridyl, optionally substituted by one or more substituents selected from the group consisting of lower alkyl, optionally substituted with halogen, oxo, hydroxy, lower alkoxy, halogen, pyrrolidinyl, morpholinyl and tanila,
(16) pyrimidinyl, optionally substituted by one or more substituents selected from the group consisting of lower alkyl and phenyl,
(17) pyridazinyl,
(18) pyrazinyl,
(19) imidazo[2,1-b]thiazolyl, optionally substituted by one or more halogen,
(20) thieno[2,3-b]pyrazinyl,
(21) 2,3-dihydroimidazo[2,1-b]thiazolyl, optionally substituted by one or more phenyl,
(22) benzothiazolyl, optionally substituted by one or more lower alkyl,
(23) indolyl, optionally substituted by one who does more substituents, selected from the group consisting of lower alkyl, lower alkanoyl and halogen,
(24) imidazo[1,2-a]pyridyl, optionally substituted by one or more lower alkyl,
(25) benzothieno, optionally substituted by one or more lower alkyl,
(26) benzimidazolyl, optionally substituted by one or more lower alkyl,
(27) 2,3-dihydrobenzo[b]Furie,
(28) benzofuran, optionally substituted by one or more halogen,
(29) indazole, optionally substituted by one or more lower alkyl,
(30) furo[2,3-C]pyridyl, optionally substituted by one or more substituents selected from the group consisting of oxo and lower alkyl,
(31) furo[3,2-C]pyridyl, optionally substituted by one or more substituents selected from the group consisting of oxo, lower alkyl, optionally substituted with halogen, halogen, furil, pyridyl and phenyl, optionally substituted by one or more lower alkoxy,
(32) thieno[2,3-e]pyridyl, optionally substituted by one or more substituents selected from the group consisting of a carbonyl group and lower alkyl,
(33) thieno[3,2-C]pyridyl, optionally substituted by one or more substituents selected from the group consisting of oxo and lower alkyl,
(34) thieno[2,3-b]pyridyl,
(35) benzo[1,3]dioxole, optionally substituted by one or more halogen,br/> (36) benzisoxazole,
(37) pyrazolo[2,3-a]pyridyl,
(38) indolizinyl,
(39) 2,3-dihydroindole, optionally substituted by one or more substituents selected from the group consisting of oxo, lower alkyl and lower alkanoyl,
(40) izochinolina, optionally substituted by one or more substituents selected from the group consisting of lower alkyl, halogen and oxo,
(41) 1,2,3,4-tetrahydro-1H-izochinolina, optionally substituted by one or more oxo,
(42) barbastella, optionally substituted by one or more lower alkoxy,
(43) 3,4-dihydroorotase, optionally substituted by one or more lower alkoxy,
(44) chinoline, optionally substituted by one or more substituents selected from the group consisting of amino, optionally substituted by one or two lower alkyl, lower alkoxy, lower alkyl and oxo,
(45) Romania, optionally substituted by one or more lower alkyl,
(46) 5,6,7,8-tetrahydroisoquinoline, optionally substituted by one or more oxo,
(47) 3,4-dihydro-1H-izochinolina, optionally substituted by one or more oxo,
(48) naphthyridine,
(49) 1,4-benzodioxane,
(50) cinnoline,
(51) khinoksalinona, or
(52) 2,3-dihydrobenzo-1,4-oxazinyl, optionally substituted by one or more substituents selected from the group consisting of lower alkyl and the CSR.

3. Connection benzodiazepine represented by the General Formula (1) or its pharmaceutically acceptable salt according to claim 2,
where R⁶and R⁷each is one of (4A), (6A), (7a), (15A), (30A), (31A), (32A), (33a), (40A) and (44a):
(4A) phenyl, optionally substituted by one or more substituents selected from the group consisting of (4A-1), (4A-4) and (4A-6):
(4A-1) cyano,
(4A-4) lower alkyl, optionally substituted by one or more halogen, and
(4A-6) pyridyl,
(6A) furil,
(7a) tanila,
(15A) pyridyl, optionally substituted by one or more lower alkyl,
(30A) furo[2,3-C]pyridyl, optionally substituted by one or more oxo,
(31A) furo[3,2-C]pyridyl, optionally substituted by one or more substituents selected from the group consisting of oxo and lower alkyl,
(32A) thieno[2,3-C]pyridyl, optionally substituted by one or more oxo,
(33a) thieno[3,2-C]pyridyl, optionally substituted by one or more oxo,
(40A) izochinolina, optionally substituted by one or more oxo, and
(44a) chinoline, optionally substituted by one or more oxo.

4. Connection benzodiazepine represented by the General formula (1) or its pharmaceutically acceptable salt according to claim 2, which is chosen from the group consisting of the following compounds:
trihydrochloride 1-ethyl-3,3,5-trimethyl-7-{3-[(2-pyridin-3-retil)pyridine-4-ylmethylamino]propoxy}-15-dihydrobenzo[b][1,4]diazepin-2,4-dione,
trihydrochloride 3,3,5-trimethyl-1-propyl-7-{3-[(2-pyridin-3-retil)pyridine-4-ylmethylamino]propoxy}-1,5-dihydrobenzo[b][1,4]diazepin-2,4-dione,
trihydrochloride 1,5 - diethyl-3,3-dimethyl-7-{3-[(2-pyridin-3-retil)pyridine-4-ylmethylamino]propoxy}-1,5-dihydrobenzo[b][1,4]diazepin-2,4-dione,
trihydrochloride 1,3,3,5-tetramethyl-7-{3-[(2-pyridin-3-retil)pyridine-4-ylmethylamino]propoxy}-1,5-dihydrobenzo[b][1,4]diazepin-2,4-dione,
the dihydrochloride of 1-ethyl-3,3,5-trimethyl-7-(3-{[2-(1-oxo-1H-isoquinoline-2-yl)ethyl]pyridine-4-ylmethylamino}propoxy)-1,5-dihydrobenzo[b][1,4]diazepin-2,4-dione,
the dihydrochloride of 1-ethyl-3,3,5-trimethyl-7-(3-{[2-(7-oxo-7H-furo[2,3-C]pyridine-6-yl)ethyl]pyridine-4-ylmethylamino}propoxy)-1,5-dihydrobenzo[b][1,4]diazepin-2,4-dione,
the dihydrochloride of N-methyl-N-(2-{pyridin-4-ylmethyl-[3-(1,3,3,5-tetramethyl-2,4-dioxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-7-yloxy)propyl]amino}ethyl)benzamide,
the dihydrochloride 1,3,3,5-tetramethyl-7-{3-[(2-methylbenzyl)-(2-pyridin-3-retil)amino]propoxy}-1,5-dihydrobenzo[b][1,4]diazepin-2,4-dione,
trihydrochloride 1,3,3,5-tetramethyl-7-{3-[(2-pyridin-3-retil)-(quinoline-4-ylmethyl)amino]propoxy}-1,5-dihydrobenzo[b][1,4]diazepin-2,4-dione,
trihydrochloride 1-ethyl-3,3,5-trimethyl-7-{3-[(3-methylpyridin-4-ylmethyl)-(2-pyridin-3-retil)amino]propoxy}-1,5-dihydrobenzo[b][1,4]diazepin-2,4-dione,
the dihydrochloride of 1-ethyl-3,3,5-trimethyl-7-(3-{[2-(2-oxo-2H-quinoline-1-yl)ethyl]pyridine-4-ylmethylamino}propoxy)-1,5-Digue is drobenko[b][1,4]diazepin-2,4-dione,
the dihydrochloride of 1-ethyl-3,3,5-trimethyl-7-(3-{[2-(7-oxo-7H-thieno[2,3-C] pyridine-6-yl)ethyl] pyridine-4-ylmethylamino}propoxy)-1,5-dihydrobenzo[b][1,4]diazepin-2,4-dione,
4-({[3-(1-ethyl-3,3,5-trimethyl-2,4-dioxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4] diazepin-7-yloxy)propyl]-[2-(1-oxo-1H-isoquinoline-2-yl)ethyl]amino}methyl)benzonitrile,
1-ethyl-3,3,5-trimethyl-7-(3-{[2-(1-oxo-1H-isoquinoline-2-yl)ethyl]thiophene-3-ylmethylamino}propoxy)-1,5-dihydrobenzo[b][1,4]diazepin-2,4-dione,
1-ethyl-7-(3-{furan-2-ylmethyl-[2-(1-oxo-1H-isoquinoline-2-yl)ethyl]amino}propoxy)-3,3,5-trimethyl-1,5-dihydrobenzo[b][1,4]diazepin-2,4-dione,
7-{3-[benzyl-(2-pyridin-3-retil)amino]propoxy}-1-ethyl-3,3,5-trimethyl-1,5-dihydrobenzo[b][1,4]diazepin-2,4-dione,
3-{[[3-(1-ethyl-3,3,5-trimethyl-2,4-dioxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-7-yloxy)propyl]-(2-pyridin-3-retil)amino]methyl}benzonitrile,
1-ethyl-3,3,5-trimethyl-7-{3-[(2-pyridin-3-ylbenzyl)-(2-pyridin-3-retil)amino]propoxy}-1,5-dihydrobenzo[b][1,4]diazepin-2,4-dione,
4-({[3-(1-ethyl-3,3,5-trimethyl-2,4-dioxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-7-yloxy)propyl]-[2-(7-oxo-7H-furo[2,3-C]pyridine-6-yl)ethyl]amino}methyl)benzonitrile,
1-ethyl-3,3,5-trimethyl-7-{3-[[2-(7-oxo-7H-furo[2,3-C]pyridine-6-yl)ethyl]-(4-trifloromethyl)amino]propoxy}-1,5-dihydrobenzo[b][1,4]diazepin-2,4-dione,
1-ethyl-3,3,5-trimethyl-7-(3-{(2-methylbenzyl)-[2-(7-oxo-7H-furo[2,3-C]pyridine-6-yl)ethyl]amino}propoxy)-1,5-dihydrobenzo[b][1,4]diazepin-2,4-dione,
1-ethyl-3,3,5-t is imethyl-7-(3-{[2-(7-oxo-7H-furo[2,3-C]pyridine-6-yl)ethyl]thiophene-2-ylmethylamino}propoxy)-1,5-dihydrobenzo[b][1,4]diazepin-2,4-dione,
the dihydrochloride of 1-ethyl-3,3,5-trimethyl-7-(3-{[2-(2-methyl-4-oxo-4H-furo[3,2-C]pyridine-5-yl)ethyl]pyridine-4-ylmethylamino}propoxy)-1,5-dihydrobenzo[b][1,4]diazepin-2,4-dione,
1-ethyl-3,3,5-trimethyl-7-(3-{[2-(4-oxo-4H-furo[3,2-C]pyridine-5-yl)ethyl]pyridine-3-ylmethylamino}propoxy)-1,5-dihydrobenzo[b][1,4]diazepin-2,4-dione,
1-ethyl-3,3,5-trimethyl-7-(3-{[2-(4-oxo-4H-thieno[3,2-C]pyridine-5-yl)ethyl]pyridine-3-ylmethylamino}propoxy)-1,5-dihydrobenzo[b][1,4]diazepin-2,4-dione,
1-ethyl-3,3,5-trimethyl-7-{3-[[2-(2-methyl-4-oxo-4H-furo[3,2-C]pyridine-5-yl)ethyl]-(4-methylpyridin-3-ylmethyl)amino]propoxy}-1,5-dihydrobenzo[b][1,4]diazepin-2,4-dione,
1-ethyl-3,3,5-trimethyl-7-(3-{(2-methylpyridin-3-ylmethyl)-[2-(4-oxo-4H-furo[3,2-C]pyridine-5-yl)ethyl]amino}propoxy)-1,5-dihydrobenzo[b][1,4]diazepin-2,4-dione,
1-ethyl-3,3,5-trimethyl-7-(3-{(4-methylpyridin-3-ylmethyl)-[2-(4-oxo-4H-furo[3,2-e]pyridine-5-yl)ethyl]amino}propoxy)-1,5-dihydrobenzo[b][1,4]diazepin-2,4-dione,
1-ethyl-3,3,5-trimethyl-7-(3-{(2-methylpyridin-3-ylmethyl)-[2-(4-oxo-4H-thieno[3,2-C]pyridine-5-yl)ethyl]amino}propoxy)-1,5-dihydrobenzo[b][1,4]diazepin-2,4-dione,
the dihydrochloride of 1-ethyl-3,3,5-trimethyl-7-{3-[[2-(2-methyl-4-oxo-4H-furo[3,2-C]pyridine-5-yl)ethyl]-(2-propylpyridine-3-ylmethyl)amino]propoxy}-1,5-dihydrobenzo[b][1,4]diazepin-2,4-dione,
the hydrochloride of N-[3-(1-ethyl-3,3,5-trimethyl-2,4-dioxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-7-yloxy)propyl]-N-(2-pyridin-3-retil)benzosulfimide,
the dihydrochloride of 7-(3-{(2,6-dimethylpyridin the n-3-ylmethyl)-[2-(4-oxo-4H-furo[3,2-C]pyridine-5-yl)ethyl]amino}propoxy)-1-ethyl-3,3,5-trimethyl-1,5-dihydrobenzo[b][1,4]diazepin-2,4-dione,
the hydrochloride of N-[3-(1-ethyl-3,3,5-trimethyl-2,4-dioxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-7-yloxy)propyl]-N-(2-pyridin-3-retil)benzamide and
N-[3-(1-ethyl-3,3,5-trimethyl-2,4-dioxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-7-yloxy)propyl]-N-[2-(1-oxo-1H-isoquinoline-2-yl)ethyl]benzosulfimide.

5. Pharmaceutical composition for prevention and/or treatment of arrhythmia, containing the compound of the benzodiazepine represented by the Formula (1), or its pharmaceutically acceptable salt according to claim 1 and a pharmacologically acceptable carrier.

6. Connection benzodiazepine represented by the Formula (1)or its salt according to claim 1 for use in pharmaceutical compositions for the prevention and/or treatment of arrhythmia.

7. Application connection benzodiazepine represented by the Formula (1), or its pharmaceutically acceptable salt according to claim 1 as a pharmaceutical composition for prevention and/or treatment of arrhythmia.

8. Application connection benzodiazepine represented by the Formula (1), or its pharmaceutically acceptable salt according to claim 1 to obtain a pharmaceutical composition for prevention and/or treatment of arrhythmia.